Pfiz­er CEO points to IRA as a fac­tor that made Seagen an at­trac­tive tar­get

One of the rea­sons Pfiz­er sought to pur­chase Seagen, as part of a $43 bil­lion deal an­nounced this morn­ing, is that the Seat­tle-based biotech will be able to with­stand the com­ing head­winds of the In­fla­tion Re­duc­tion Act and the Medicare price ne­go­ti­a­tions that come with it.

Un­like some of his phar­ma CEO peers who have lam­bast­ed the new law, Pfiz­er CEO Al­bert Bourla told in­vestors on a call this morn­ing that there are two spe­cif­ic fac­tors per­tain­ing to the IRA that will ac­tu­al­ly help with the com­bo of Pfiz­er and Seagen mov­ing for­ward:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER